Researchers Identify New Therapeutic Targets for Small Cell Lung Cancer

Small cell lung cancer is a devastating disease that is diagnosed in 30,000 people a year in the U.S. and accounts for roughly 15 percent of lung cancer cases.

Survival for patients with small cell lung cancer is poor and few therapies are available. A protein termed ASCL1 has been identified by UT Southwestern Medical Center researchers, that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.

The new findings identify ASCL1 as an important therapeutic target for small cell lung cancer, for which there have been few changes in treatment for the past 30 years."We used a genetically engineered mouse model that develops human-like small cell lung cancer and identified two regulatory pathways that in turn revealed vulnerabilities in this cancer," said senior author Dr. Jane E. Johnson, Professor of Neuroscience and Pharmacology and a member of UT Southwestern's Harold C. Simmons Comprehensive Cancer Center.

Hybrid Immune Cells in Early-Stage Lung Cancer Spur Anti-Tumor T Cells
PHILADELPHIA - The microenvironment of tumors is a mix of cell types, mostly comprised of inflammatory cells.

‘Small cell lung cancer is a devastating disease that is diagnosed in 30,000 people a year in the U.S. and accounts for roughly 15 percent of lung cancer cases.’

The findings, published in the journal Cell Reports, are important because survival for patients with small cell lung cancer is poor and few therapies are available. "Small cell lung cancer is a devastating disease that is diagnosed in 30,000 people a year in the U.S. and accounts for roughly 15 percent of lung cancer cases. Most patients survive one year or less and therapy has not changed significantly in 30 years. Our work shows the possibility of developing entirely new types of targeted therapies for small cell lung cancer by focusing on ASCL1," said Dr. John D. Minna, Professor and Director of the Hamon Center for Therapeutic Oncology Research, and Director of the W.A.

"Tex" and Deborah Moncrief Jr. Center for Cancer Genetics. He is Professor of Internal Medicine and Pharmacology, co-directs the Experimental Therapeutics of Cancer Program at the Simmons Cancer Center, and holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research.

Signs and symptoms of small cell lung cancer include coughing, shortness of breath, and chest pain, and the rapid development of widely spread disease around the patient's body. Smoking is the major risk factor for small cell lung cancer according to the National Cancer Institute, which helped fund the study along with the Cancer Prevention and Research Institute of Texas. The team of researchers, which included Dr. Melanie H. Cobb, Interim Director of the Simmons Cancer Center and Professor of Pharmacology, determined that the ASCL1 protein found in most small cell lung cancer tumors is required for formation of the disease.

Hybrid Immune Cells Identified in Early-Stage Lung Cancer Tumors
A unique subset of tumor associated neutrophils (TANs) have been idenfied in samples from early-stage human lung cancers.

When researchers deleted ASCL1 in the lungs of mice genetically engineered to develop small cell lung cancer, this loss prevented development of the cancer. Additionally, researchers were able to differentiate between the tumor-promoting function of ASCL1 and a related protein, NEUROD1, in small cell lung cancer. Some small cell lung cancers expressed ASCL1 whereas others expressed NEUROD1, and although the two genes regulate different processes in the cells, both appear to control genes that are important in driving this cancer.

Dr. Johnson, holder of the Shirley and William S. McIntyre Distinguished Chair in Neuroscience, has been studying the roles of ASCL1 in the developing nervous system for many years , and was able to identify new roles for the protein in small cell lung cancer using UT Southwestern's Genomics and Microarray Core facility, which provides cutting-edge molecular technologies and services to hundreds of investigators pursuing different research projects.

Middle-aged Patients at Greater Risk of Late Stage Lung Cancer
Patients between ages 50 to 64 years are more likely to be diagnosed with late stage lung cancer than older patients, reveals new study.

Source-Eurekalert

Surgery Prolongs Life in Lung Cancer Patients
A better survival rate was seen when surgery in combination with chemotherapy was done compared to radiation or only chemotherapy in lung cancer patients.